High normal blood pressure: To treat or not to treat?

Journal of Human Hypertension

Volumn 29, Issue 1, 2015, Pages 7-8

  Ahmed, A ^a   Senior, R ^a,b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ANTIHYPERTENSIVE THERAPY; BAYES THEOREM; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; CONSENSUS; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET; EARLY INTERVENTION; ELECTROCARDIOGRAPHY; EXERCISE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HOSPITALIZATION; HUMAN; HYPERTENSION; MASKED HYPERTENSION; MICROALBUMINURIA; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; THERAPY DELAY; WEIGHT CONTROL; WOMEN'S HEALTH; COMPLICATION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; MALE; PATHOPHYSIOLOGY;

BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84927177525     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.24     Document Type: Note

References (18)

1. Swales JD. Platt versus Pickering. An Episode in Recent Medical History, Vol. 8. Keynes Press (British Medical Association), London; 1985, pp. vii, 155.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
4. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991; 17(1): 22-27.
5. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686.
6. Vasan R, Larsen MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB et al. Impact of high normal blood pressure on the risk of cardiovascular disease. New Engl J Med 2001; 345: 1291-1297.
7. Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H et al. Upper normal blood pressure predict incident atrial fibrillation in healthy middle aged men: a 35-year follow-up study. Hypertension 2012; 59: 198-204.
8. Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ 2007; 335: 432.
9. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: meta analysis. J Hypertens 2007; 25: 2193-2198.
10. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. J Hypertens 2008; 26: 1715-1725.
11. Pewsner D, Juni P, Egger M, Battaglia M, Sundstorm J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 2007; 335: 711.
12. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Heart Outcomes Prevention Evaluation (HOPE) investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-1621.
13. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2350-2356.
14. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007; 50: 984-990.
15. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296: 1242-1248.
16. OKin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007; 147: 311-319.
17. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Karioti N et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. New Engl J Med 2006; 354: 1685-1697.
18. Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohn M et al. The PHARAOStudy: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-1496.